Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density

Russell RG(2006)Bisphosphonates: from bench to bedside Ann N Y Acad Sci 1068 367-401

Watson J(2007)Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005 Eur J Clin Pharmacol 63 843-849

Wise L(2013)Bisphosphonate drug holiday: who, when and how long Ther Adv Musculoskelet Dis 5 107-111

Green J(2013)Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013 Maturitas 75 392-396

Diab DL(2012)Bisphosphonates for osteoporosis—where do we go from here? N Engl J Med 366 2048-2051

Watts NB(2010)The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program J Am Dent Assoc 141 1365-1370

Compston J(2010)Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur N Engl J Med 362 1761-1771

Bowring C(2008)Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy Osteoporos Int 19 733-759

Cooper A(2006)Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite Bone 38 617-627

Cooper C(2013)Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday Am J Med 126 13-20

Russell RG(2006)Bisphosphonates: from bench to bedside Ann N Y Acad Sci 1068 367-401

Watson J(2007)Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005 Eur J Clin Pharmacol 63 843-849

Wise L(2013)Bisphosphonate drug holiday: who, when and how long Ther Adv Musculoskelet Dis 5 107-111

Green J(2013)Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013 Maturitas 75 392-396

Diab DL(2012)Bisphosphonates for osteoporosis—where do we go from here? N Engl J Med 366 2048-2051

Watts NB(2010)The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program J Am Dent Assoc 141 1365-1370

Compston J(2010)Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur N Engl J Med 362 1761-1771

Bowring C(2008)Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy Osteoporos Int 19 733-759

Cooper A(2006)Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite Bone 38 617-627

Cooper C(2013)Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday Am J Med 126 13-20